Capacity to deliver intravenous Alzheimer's disease (AD) treatments could constitute an obstacle to access in addition to AD specialist and PET scan capacity.
Objective
We aim to estimate the overall capacity for AD treatment infusions compared to expected demand in the United States.
Methods
We used published data and a survey of infusion sites to estimate the capacity to deliver AD treatments in physician offices, hospitals, standalone centers and at patients’ homes from 2024 to 2033 relative to demand.
Results
Capacity for intravenous AD treatments is predicted to increase from 370,000 in 2024 to 5.2 million infusions in 2033. Nevertheless, a significant shortfall of over 13 million infusions remains in 2033, which would imply delayed access for 2.2 million patients.
Conclusions
Limited infusion capacity could impede AD treatment access and result in avoidable disability progression. Expansion of capacity is needed in the short run until treatments with alternative routes of administration become available.
GillisCMontenigroPNejatiM, et al.Estimating prevalence of early Alzheimer's disease in the United States, accounting for racial and ethnic diversity. Alzheimers Dement2023; 19: 1841–1848.
2.
Van DyckCJohnsonKSperlingR, et al.Lecanemab for early Alzheimer’s disease: long-term outcomes, predictive biomarkers and novel subcutaneous administration. In: Clinical trials on Alzheimer’s disease (CTAD). Boston, MA, USA: Eisai, 2023. https://www.eisai.com/news/2023/news202368.html (accessed on August 2025).
3.
SimsJRZimmerJAEvansCD, et al.Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA2023; 330: 512–527.
4.
LiuJHlávkaJHillestadRJ, et al.Assessing the preparedness of the US health care system infrastructure for an Alzheimer's treatment. Santa Monica, CA, USA: RAND, 2017. https://www.rand.org/pubs/research_reports/RR2272.html
5.
HlavkaJPMattkeSLiuJL. Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer's treatment. Rand Health Q2019; 8: 2.
6.
LiuJHlávkaJCoulterD, et al.Assessing the preparedness of the Canadian health care system infrastructure for an Alzheimer's treatment. Santa Monica, CA, USA: RAND, 2019. https://www.rand.org/pubs/research_reports/RR2744.html
BlackSEBuddNNygaardHB, et al.A model predicting healthcare capacity gaps for Alzheimer's disease-modifying treatment in Canada. Can J Neurol Sci2024; 51: 487–494.
9.
MattkeSCorrêa dos Santos FilhoOHansonM, et al.Preparedness of the Brazilian health-care system to provide access to a disease-modifying Alzheimer's disease treatment. Alzheimers Dement2023; 19: 375–381.
10.
MattkeSTangYHansonM. Expected wait times for access to a disease-modifying Alzheimer’s treatment in England: a modelling study. J Health Serv Res Policy2024; 29: 69–75.
11.
MattkeSHansonM. Expected wait times for access to a disease-modifying Alzheimer's treatment in the United States. Alzheimers Dement2022; 18: 1071–1074.
12.
RobertsMHErdeiE. Comparative United States autoimmune disease rates for 2010–2016 by sex, geographic region, and race. Autoimmun Rev2020; 19: 102423.
13.
SilberAAthavaleAKulkarniA, et al.HSD48 US infusion center capacity to accommodate anti-amyloid treatments for Alzheimer’s disease: a quantitative survey. Value Health2024; 27: S229.
RobeySDavidFS. Drug launch curves in the modern era. Nat Rev Drug Discov2017; 16: 13–14.
17.
SabbaghMNZhaoCMahendranM, et al.Characterizing the journey of early Alzheimer’s disease in patients initiating lecanemab treatment in the United States: a real-world evidence study. Neurol Ther2025; 14: 1115–1127.
18.
ZhouFFEssienURSouzaJM, et al.Disparities in early lecanemab uptake among US Medicare beneficiaries. JAMA Network Open2025; 8: e2511711.
19.
PaczynskiMHofmannAPoseyZ, et al.Lecanemab treatment in a specialty memory clinic. JAMA Neurol2025; 82: 655–665.
20.
BregmanNNathanTShirD, et al.Lecanemab in clinical practice: real-world outcomes in early Alzheimer’s disease. Alzheimers Res Ther2025; 17: 119.
21.
MoonJFerrerA. Lecanemab in clinical practice: real-world treatment outcomes from a retrospective neurological clinic case series review in early Alzheimer’s disease (P12-3.008). Neurology2025; 104: 4827.
MattkeSChoSKBittnerT, et al.Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: projecting the impact on the cost and wait times. Alzheimers Dement (Amst)2020; 12: e12081.
26.
PradosMJLiuYJunH, et al.Projecting the long-term societal value of a disease-modifying treatment for Alzheimer's disease in the United States. Alzheimers Dement2022; 18: 142–151.
27.
LiuJLBakerLChenA, et al.Modeling Early Detection and Geographic Variation in Health System Capacity for Alzheimer's Disease - Modifying Therapies. Santa Monica, CA: RAND Corporation, 2024.
CummingsJZhouYLeeG, et al.Alzheimer's disease drug development pipeline: 2024. Alzheimers Dement (N Y)2024; 10: e12465.
31.
SwansonCMartényiFTookerRE, et al.Phase 1 single and multiple dose clinical trials (ASCENT-1 and ASCENT-2) for dose-finding of PRX012 in participants with biologically confirmed Alzheimer's disease. Alzheimers Dement2024; 20: e090487.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
